Abbott (NYSE:ABT) announced today that it completed its previously announced acquisition of Bigfoot Biomedical. Pursuant to the terms of the merger agreement, upon completion, Bigfoot became a wholly-owned subsidiary of Abbott. The companies declined to disclose financial terms. Abbott announced on Sept. 5 that it entered into a definitive agreement to acquire the smart insulin management […]
Bigfoot Biomedical
Abbott to acquire insulin management company Bigfoot Biomedical
Abbott (NYSE:ABT) announced today that it entered into a definitive agreement to acquire smart insulin management company Bigfoot Biomedical. The transaction remains subject to customary closing conditions and the companies declined to disclose financial terms. They expect it to close in the third quarter of 2023. Abbott has a longstanding relationship with Bigfoot going back […]
The biggest stories from the American Diabetes Association (ADA) 2023 Scientific Sessions
As it does every year, this past week, the American Diabetes Association convened its Scientific Sessions to bring together leaders in the diabetes space. At last year’s event, next-generation technologies from the big hitters took the spotlight. The 83rd iteration this past week produced a range of new studies, product updates and positive news for […]
Real-world data supports Bigfoot Biomedical diabetes management platform
Bigfoot Biomedical today announced study data demonstrating the potential of its Bigfoot Unity system for diabetes management. The FDA-cleared Bigfoot Unity platform aims to simplify continuous glucose monitors (CGMs) and the data they produce. It features a smart insulin pen cap, which takes data from a CGM and informs the patient exactly how much insulin […]
Bigfoot Biomedical acquires insulin titration algorithm developed at McGill University
Bigfoot Biomedical announced today that it acquired a reinforcement learning algorithm for insulin titration from McGill University. Developers at McGill designed the algorithm to observe how well people with insulin-requiring diabetes respond to a particular dose. It provides a recommended adjustment based on the body’s response. Milpitas, California-based Bigfoot said the developers built the algorithm […]
Bigfoot Biomedical takes next steps for its holistic diabetes management platform
After executing a significant IP sale, Bigfoot Biomedical looks to double down on its diabetes management platform. Less than two years ago, Bigfoot Biomedical launched its Bigfoot Unity platform in some U.S. states. CEO Jeffrey Brewer last year called it a “transformational attempt” to simplify CGMs and the data they produce. It features a smart […]
Bigfoot Biomedical wins FDA clearance for Bigfoot Unity Android app
Bigfoot Biomedical announced today that it received FDA 510(k) clearance for the Android version of its Bigfoot Unity mobile app. Milpitas, California-based Bigfoot received FDA clearance for its diabetes management platform in May 2021. Its initial rollout featured compatibility with iOS devices. The first-of-its-kind system includes connected smart pen caps designed to recommend insulin doses […]
Insulet acquires insulin pump patents from Bigfoot Biomedical for $25M
Insulet (Nasdaq:PODD) announced today that it acquired assets related to Bigfoot Biomedical’s pump-based automated insulin delivery technologies. Acton, Massachusetts-based Insulet paid $25 million to acquire the AID assets. These include certain Bigfoot patents related to pumps that may be used for AID therapy. Insulet already develops its own AID technology with its Omnipod platform. The […]
6 drug delivery innovations you need to know
From wearable insulin delivery devices to drug-eluting implants and everything in between, drug delivery innovation never stops. Vaccines, life-saving therapeutics, vision-correcting drugs and more are being developed and marketed for delivery with all kinds of technologies. More than a year ago, we compiled a list of eight drug delivery innovations you need to know. With […]
The biggest stories from the American Diabetes Association (ADA) 2022 Scientific Sessions
For the 82nd time, the American Diabetes Association (ADA) Scientific Sessions convened to highlight all the innovations within the diabetes technology space. Major players like Dexcom, Medtronic, Abbott, Insulet and more continue to plug along, while companies like Bigfoot Biomedical, One Drop and others shared data backing the technology that they bring to the table. […]
